Skip to content
DataLookout
Menu

NCT03386513

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

StatusCompleted
PhasePhase 1/2
SponsorAbbVie
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 32 versions: 30 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words Show 6 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Trial completed
    • Trial sites reduced: 29 → 18 locations
    • Study completion date changed from estimate of Dec 30, 2026 to Oct 1, 2026
    • Secondary endpoints: details revised at 18 of 23 entries
    • Publications: details revised at 2 of 2 entries
  2. Notable Primary completion pushed from Sep 6, 2023 to Oct 2, 2024
    • Primary endpoint(s) modified
    • Results posted: Sep 4, 2026
    v31
  3. Notable Primary completion date: Sep 6, 2023 to Oct 2, 2024
    • Primary endpoint revised
    • Study sites: 28 to 29
    • Secondary endpoints: 11 to 23
    v30
  4. Minor Study completion date: Dec 1, 2025 to Dec 30, 2026v29
  5. Notable Lead sponsor: ImmunoGen, Inc. to AbbViev28
Show 24 earlier versionsHide 24 earlier versions
  1. Minor Primary completion date changed from estimate of Dec 2024 to Sep 6, 2023
    • Study completion date: Dec 2025 to Dec 1, 2025
    v27
  2. Notable Eligibility criteria expanded, about 67 wordsv26 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 252 to confirmed 179
    • Study sites: 27 to 28
    • Study description shortened, about 33 words
  3. Notable Eligibility criteria expanded, about 24 words
    • Study sites: 24 to 27
    v25
  4. Minor Study sites: 23 to 24v24
  5. Notable Primary completion date: Jun 2022 to Dec 2024
    • Eligibility criteria shortened, about 76 words
    • Study sites: 15 to 23
    • Study completion date: Dec 2022 to Dec 2025
    v23
  6. Minor Site details revised at 3 of 15 sitesv22
  7. Minor Site details revised at 1 of 15 sitesv21
  8. Minor Site details revised at 1 of 15 sitesv20
  9. Minor Study sites revised (15)
    • Study title shortened, about 3 words
    v18
  10. Notable Primary completion date: Aug 2020 to Jun 2022v17 Show 8 more changesShow less
    • Eligibility criteria expanded, about 8 words
    • Primary endpoint revised
    • Enrollment target: 212 to 252
    • Study sites: 12 to 15
    • Study completion date: Feb 2021 to Dec 2022
    • Secondary endpoints: 6 to 11
    • Study description shortened, about 13 words
    • Collaborators shortened, about 2 words
  11. Notable Phase: Phase 1 to Phase 1/2
    • Eligibility criteria expanded, about 94 words
    • Enrollment target: 155 to 212
    • Study sites: 11 to 12
    v16
  12. Minor Site contacts updated at 5 of 11 sitesv15
  13. Notable Eligibility criteria expanded, about 26 words
    • Start date: Jan 4, 2018 to Jan 2, 2018
    v14
  14. Minor Study sites: 7 to 11v13
  15. Minor Study sites: 6 to 7v12
  16. Minor Study sites: 5 to 6v10
  17. Minor Study sites: 4 to 5v9
  18. Minor Site contacts updated at 1 of 4 sitesv8
  19. Notable Eligibility criteria revisedv7
  20. Minor Study sites: 3 to 4v6
  21. Minor Study sites: 1 to 3v5
  22. Minor Site contact updatedv4
  23. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2018 to Jan 4, 2018
    • Site details revised
    v3
  24. Minor Start date: Dec 2017 to Jan 2018v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Participants
Timeframe: Up to approximately 81 months

Secondary (23)

Dose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs)
Maximum Plasma Concentration (Cmax) of IMGN632 (Antibody Drug Conjugate [ADC]) and Total Antibody
Cmax of FGN849
Area Under the Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of IMGN632 (ADC) and Total Antibody
Show 18 moreShow less
AUC0-last of FGN849
Number of Participants With Anti-drug Antibodies (ADAs) at Any Post-baseline Visit
Dose Escalation Phase: Overall Response Rate (ORR), As Assessed by Investigator in Participants With AML
Dose Escalation Phase: CR+CRh Rate, As Assessed by Investigator in Participants With AML
Dose Escalation Phase: CR+CRh+CRi Rate, As Assessed by Investigator in Participants With AML
CCR Rate As Assessed by Investigator in Participants With Relapsed/Refractory (R/R) BPDCN
Duration of CCR (DOCR) As Assessed by Investigator in Frontline De Novo BPDCN Participants With CR or CRc
DOCR As Assessed by Investigator in R/R BPDCN Participants With CR or CRc
DOCR As Assessed by Investigator in Total Frontline BPDCN Participants With CR or CRc
Number of Participants With TEAEs in Participants Who Received IMGN632 As a Single Agent at the RP2D Level (0.045 mg/kg)
Rate of CR+CRc+CRh As Assessed by Investigator in Total R/R BPDCN Participants
Duration of CR+CRc+CRh As Assessed by Investigator in Total R/R BPDCN Participants
ORR As Assessed by Investigator in Total R/R BPDCN Participants
Duration of Overall Response As Assessed by Investigator in Total R/R BPDCN Participants
Overall Survival in Total R/R BPDCN Participants
CCR Rate As Assessed by Investigator in All Frontline BPDCN Participants With Post-Treatment Consolidative Stem Cell Transplant (SCT)
CCR Rate As Assessed by Investigator in All R/R BPDCN Participants With Post-Treatment Consolidative SCT
Percentage of Participants With Post-baseline Transfusion Independence in BPDCN Participants

Arms and interventions

Escalation and ExpansionExperimental

Escalation: IMGN632 was administered by IV on 2 different schedules for participants with relapsed/refractory AML, ALL, or BPDCN. Expansion: IMGN632 was administered by IV: * Cohort 1: Relapsed or refractory BPDCN participants who have received 1-3 prior systemic therapies (incl. tagraxofusp-erzs and/or any other systemic therapy deemed appropriate for the treatment of BPDCN) * Cohort 2: Relapsed AML * Cohort 3: Relapsed or refractory ALL * Cohort 4: Other relapsed or refractory hematologic malignancies * Cohort 5: Relapsed or refractory AML at alternate dose or schedule * Cohort 6: Pivotal cohort for frontline BPDCN participants who have not received prior systemic therapy and participants with frontline BPDCN who have prior or concomitant hematologic malignancy (PCHM) and have not received prior systemic therapy.

Drugs: IMGN632

Sites

18 sites in 4 countries

United States 11, France 4, Italy 2, Spain 1